Over-subscribed Series B of $70M led by a broad consortium of strategic and institutional investors; funding to accelerate product development, regulatory filing and international rollout. Support from robotics pioneer Fred Moll noted.
About Vitestro
Dutch MedTech company developing an autonomous robotic phlebotomy system combining robotics, multimodal imaging and AI to automate diagnostic blood draws (Aletta® ARPD™).
Utrecht, Netherlands
Read Company ProfileFrequently Asked Questions
What type of funding round did Vitestro raise?
Vitestro raised a series-b round.
How much did Vitestro raise in its series-b?
Vitestro raised $70,000,000 USD in its series-b.
When did Vitestro raise its series-b?
Vitestro raised its series-b on 2026-03-11.
Who invested in Vitestro's series-b?
The investors in Vitestro's series-b are: Labcorp Venture Fund, Mayo Clinic, Sutter Health, InterVest, MGFO, PGGM, Puma, ROM Utrecht, Invest-NL, EIC Fund, Fred Moll, NYBC Ventures, Sonder Capital.
What type of investment was Vitestro's series-b?
Vitestro's series-b was a equity investment.
How will Vitestro use the funds from its series-b?
Vitestro plans to use the funds for: further development of robotic platform, development of next-generation Aletta® ARPD™, clinical studies expansion, preparation for regulatory approvals (FDA De Novo pathway), scaling production, international expansion and building sales/distribution, pilot programs with hospitals.